ArticlePatient preference and adherence2026
A Multidimensional Framework for Pharmaceutical Care to Enhance Medication Adherence and Patient Engagement: The CMO-MAPEX Model.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop Capacity-Motivation-Opportunity MAPEX (CMO-MAPEX), a multidimensional, patient-centred and operational framework to guide medication-adherence support in outpatient pharmaceutical care. Methods: A six-stage framework-development process was undertaken. First, a narrative scoping synthesis identified behavioural, experiential and organisational determinants of medication adherence relevant to outpatient pharmaceutical care. Second, key constructs were extracted and coded into a shared analytic matrix. Third, framework analysis was applied to cluster constructs into higher-order domains. Fourth, an integrative synthesis aligned the emergent CMO structure with evidence on adherence, treatment burden, patient experience and hybrid-care models. Fifth, the conceptual architecture was translated into a structured clinical workflow incorporating CMO-based assessment, a three-level complexity stratification system, domain-specific intervention families and hybrid follow-up rules. Finally, a multidisciplinary expert panel reviewed and refined the framework to ensure ecological validity and feasibility in routine practice. Results: The analysis yielded a stable three-domain structure-Capacity, Motivation and Opportunity-capturing patients' ability to manage treatment, their beliefs and emotional readiness, and the contextual conditions enabling or hindering adherence. These domains were operationalised through assessment indicators, complexity-based stratification, targeted intervention mapping and longitudinal hybrid-care pathways. Patient-reported outcome and experience measures were embedded as core components to monitor treatment burden, preferences and experience, and to support dynamic re-stratification and adjustment of follow-up intensity over time. Conclusion: CMO-MAPEX provides a pragmatic and scalable framework that translates adherence theory into patient-centred pharmaceutical care. By integrating behavioural determinants, patient experience and hybrid-care organisation within a single operational structure, it offers a reproducible approach to tailoring adherence support according to patient preferences and complexity in outpatient settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.